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Abstract 
Mitochondria are extensively identified for their bioenergetic capacities; 
however, recently these metabolic hubs are increasingly being appreciated as 
critical regulators of numerous cellular signaling systems. Mitochondrial 
reactive oxygen species have evolved as a mode of cross-talk between 
mitochondrial function and physiological systems, to sustain equipoise and 
foster adaption to cellular stress. Redox signaling mediated by exaggerated 
mitochondrial-ROS has been incriminated in a plethora of disease 
pathologies. Excessive production of mitochondrial-ROS is intrinsically linked 
to mitochondrial dysfunction Furthermore; mitochondrial dysfunction is a key 
facilitator of oxidative stress, inflammation, apoptosis and metabolism. These 
are key pathogenic intermediaries of pre-eclampsia, hence we hypothesize 
that mitochondrial dysfunction is a pathogenic mediator of oxidative stress in 
the pathophysiology of pre-eclampsia. We hypothesize that mitochondrial-
targeted antioxidants may restrain production of ROS-mediated deleterious 
redox signaling pathways. If our hypothesis proves correct, therapeutic 
strategies directly targeting mitochondrial superoxide scavenging should be 
actively pursued as they may alleviate maternal vascular dysfunction and 
dramatically improve maternal and fetal health worldwide. 
 
 
 
 
 
 
Introduction: 
Pre-eclampsia is a multisystemic disorder of pregnancy, which affects more 
than eight million pregnancies worldwide annually and is the leading cause of 
maternal death. Pre-eclampsia is clinically defined as hypertension and 
proteinuria with onset following the 20th week of pregnancy. Despite intensive 
investigation, the pathophysiology of pre-eclampsia remains largely unknown 
but it appears that decreased placental perfusion, resulting from deficient 
invasion of the maternal uterine wall underlines the current perception for the 
pathology of pre-eclampsia (1). During uncomplicated pregnancy maternal 
uterine spiral arteries are remodeled by invading fetal extravillous and 
endovascular trophoblasts (2).  
 
In pre-eclampsia, there is substantial evidence of shallow trophoblast invasion 
of uterine vasculature, with only superficial decidual regions of the vascular 
wall undergoing transformation (3). Dysfunctional placentation in early 
pregnancy is thought to propagate an exaggerated hypoxic/ischemia placental 
environment. Placental ischemia is inherently linked to elevated production 
and secretion of placental-derived circulatory mediators, including anti-
angiogenic factors, soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble 
endoglin (sEng), which induce widespread maternal endothelial dysfunction 
(1). Failure to remodel spiral arteries results in high-pressure blood-flow 
mediated placental damage and intermittent fluctuations in oxygen delivery, 
which expose the placenta to oxidative stress (4). Uncomplicated pregnancy 
is itself a state of oxidative stress as a result of augmented maternal 
metabolism and the subsequent metabolic activity of the placenta. However, 
during pre-eclampsia the compensatory properties regulating the placental 
oxidative state are aggravated, leading to increased production of pathogenic 
factors and subsequent vascular dysfunction. During pre-eclampsia, oxidative 
stress manifests in both the placenta and maternal circulation (4), with 
evidence of reduced antioxidant defences (5), elevated free radical formation, 
placental lipid peroxides and isoprostanes (6).  
 
Hypothesis 
We hypothesize that dysregulation of mitochondrial function modulates 
oxidative damage, which is evident in the pathogenesis of pre-eclampsia. We 
propose that mitochondrial-targeted antioxidant therapeutics will alleviate 
mitochondrial dysfunction and the aberrant regulation of mitochondrial 
reactive oxygen species (mROS) and consequently ameliorate the pathologic 
clinical characteristics of pre-eclampsia. 
 
Basis for the hypothesis 
 
Mitochondria 
Mitochondria are dynamic intracellular double membrane organelles, located 
within the cytoplasmic zone of eukaryotic cells. Mitochondria are empirically 
known for their core involvement in the energy transduction process resulting 
in adenosine triphosphate (ATP) production from metabolic fuels. The 
mitochondrion consist of two phospholipid bilayers which subdivide the 
organelle into four sectors including, the outer membrane, the inner 
membrane space, inner membrane and matrix (7). The machinery required for 
efficient operation of oxidative phosphorylation is retained in the inner 
mitochondrial membrane and hence this is the site of mROS generation. 
 
Mitochondria are unique organelles as they possess their own DNA (mtDNA) 
within the cell, distinct from the nucleus. Mitochondrial DNA is located in the 
mitochondrial matrix and encodes 13 polypeptides required for oxidative 
phosphorylation, while the remaining proteins required for efficient 
mitochondrial function are nuclear-encrypted and shuttled into the 
mitochondria (7). Mitochondria are metabolic hubs that repeatedly adjust their 
number, size, structure and dynamics in response to both intracellular and 
extracellular stimuli respectively. These metabolic units consume 90% of the 
O2 content in eukaryotic cells for oxidative phosphorylation and subsequent 
ATP synthesis (8). Consequently, the mitochondrion retains the highest 
volume of antioxidants in eukaryotic cells (9).  
 
Mitochondrial Function: Oxidative Phosphorylation 
Historically, the primordial function of mitochondria is the synthesis of ATP by 
oxidative phosphorylation via the transfer of electrons through a series of 
multi-subunit complexes (10). Complexes I, II, III and IV configure the electron 
transport chain (ETC) on the inner mitochondrial membrane. Tricarboxylic 
acid cycle (TCA) products NADH and succinate, donate electrons to Complex 
I (NADH:ubiquinone oxidoreductase) and Complex II (Succinate: ubiquinone 
oxidoreductase) respectively. These electrons are passed to ubiquinone and 
subsequently transported to Complex III (ubiquinol:cytochrome C 
oxidoreductase) (10). Electrons then shuttle to cytochrome C and flow to 
Complex IV (cytochrome C oxidase), where they finally reduce oxygen to 
water. The energy released at Complex I, III and IV is utilized to pump protons 
to the inner membrane space. This proton motive force generates a gradient 
and the mitochondrial membrane potential (MMP). Complex V (ATP synthase) 
links proton flow down this gradient to formulate ATP which fuels widespread 
metabolic processes (11). 
 
Reactive Oxygen Species (ROS) 
Reactive oxygen species are derived from the one electron reduction of 
oxygen and are relatively short-lived in the cell. There are numerous potential 
sources of ROS within the cell, including NADPH oxidases, xanthine oxidase 
and cytochrome p450 intracellular enzymes (12), however our hypotheses will 
focus on mitochondrial-generated ROS. Mitochondria are the major cellular 
producers of ROS. Mitochondrial ROS were initially described as by-products 
of oxidative phosphorylation, however, exciting new evidence has established 
mROS as important physiological regulators of intracellular signaling 
pathways, including differentiation, immune cell activation and autophagy 
(13). Electrons “leak” while being transferred between complexes in the ETC, 
in particular at Complex I and III respectively. The one electron reduction of 
oxygen by the respiratory chain generates superoxide, in isolation this ROS 
isn’t very potent, however it can react with nitric oxide leading to the 
production of the mercurial reactive nitrogen species peroxynitrite (14).  
 
In physiological conditions, most superoxide is effectively transformed to 
hydrogen peroxide (H2O2) by superoxide dismutase 2 (SOD2) in the 
mitochondrial matrix and by SOD1 in the intermembrane space. H2O2 is the 
main redox signal as unlike superoxide it can easily shuttle through the 
mitochondrial membrane into the cytoplasm of the cell (15). H2O2 can merge 
with ferrous ions leading to the creation of the highly reactive hydroxyl radical 
which causes widespread deleterious oxidative damage, often seen in 
numerous pathologies (12). Given their potency, the signaling capacity of 
mROS is tightly regulated by numerous systems within mitochondria. 
Primarily, H2O2 is fully reduced to water by various antioxidant enzymes 
including peroxiredoxins, glutathione peroxidases and catalases. 
Peroxiredoxins are highly abundant in mitochondria and are hypothesized to 
be the most significant scavenger of nanomolar levels of H2O2 (13). 
Glutathione peroxidases are less abundant and operating with reduced 
glutathione as a cofactor are proposed to scavenge ROS at higher 
intracellular concentrations. Catalase has an inferior affinity for H2O2 and is 
limited to peroxisomes (16). 
 
Regulation of mROS is not only controlled by antioxidant scavengers, but also 
by factors mediating mROS production including increased mitochondrial 
membrane potential, reduced oxygen levels, calcium concentration and 
inefficient mitophagy. Mitochondria and mROS are critical redox signaling 
nodes. Redox signaling ensues when a biological system changes its 
response to a shift in the level of a specific ROS or a swing in the redox state 
of a responsive group (15). mROS promote redox signaling by causing a 
reversible post-translation modification, affecting the activity of the protein. 
H2O2 covalently modifies thiol groups of specific cysteine residues located 
within redox-sensitive target proteins. If the modification occurs at an active 
site, the impact on the protein is loss of function, however thiol oxidation can 
also regulate the activity of target proteins in numerous other ways including, 
altering binding affinity, modifying activity of a transporter (12). Alternative 
redox signals can cause irreversible alkylation of thiols as is evident in the 
activation of certain transcription factors (15). 
 
Mitochondrial Dysfunction 
Mitochondrial dysfunction plays a critical role in numerous human pathologies 
predominantly due to the prominent function of dynamic mitochondria in 
cellular metabolism. There are a number of different protagonists that 
participate in perturbing the status of mitochondria in eukaryotes, these 
include decreased ATP production, loss of mitochondrial transmembrane 
potential with subsequent increase in mROS production, calcium 
dysregulation and mtDNA damage (11). Excessive oxidative damage, 
resulting from mitochondrial disruption is evident in the pathophysiology of 
various disease states including atherosclerosis and diabetes. Mitochondrial 
DNA is extremely susceptible to oxidative damage given its close proximity to 
ETC in the mitochondrial matrix and its paucity of protective histones and 
chromatin (17). The consequence of mtDNA damage has garnered significant 
attention in the immunology field recently when it was established that mtDNA 
act as a damage-associated molecular patterns (DAMPs) and activate the 
innate immune system in certain pathologies (18).  
 
Distorted mitochondrial dynamics has additionally been mooted as potential 
instigators of mitochondrial dysfunction. Mitochondria exist as tubular network 
in cells, they constantly endure fission and fusion events to preserve and 
regulate their structure and integrity. Mitochondrial fusion involves extending 
and tethering of neighboring mitochondria to form the filamentous network, 
while fission describes the division of mitochondria. Mitochondrial 
homeostasis is vital to maintain efficiency, hence exaggerated dysregulation 
of either of these two mechanisms leads to mitochondrial dysfunction and 
subsequent elevation in mROS (7).  
 
The health of mitochondria is in part mediated by their biogenesis, the 
inducible transcriptional co-activator peroxisome proliferator activated 
receptor γ co-activator 1-α (PGC-1α) is a well characterized pleiotropic 
orchestrator of mitochondrial biogenesis, homeostasis and mediates a ROS 
defense. Abnormal PGC-1α signaling can lead to diminished mitochondrial 
biogenesis and contribute to dysregulated metabolic outcomes (19). Healthy 
functioning mitochondria enforce certain quality control mechanisms to 
eradicate damaged mitochondria. Mitophagy is a subtype of macroautophagy 
where damaged mitochondria are sequestered in autophagosomes and 
removed and the constituents recycled for new biosynthesis (13). Disturbance 
of this homeostatic mechanism can result in increased occupation of 
damaged mitochondria and detrimental oxidative damage. 
 
 
 
Evaluation of the hypothesis 
 
Evidence of mitochondrial dysfunction in pre-eclampsia 
There is substantial circumstantial evidence to link mitochondrial dysfunction 
with pre-eclampsia, including oxidative stress, inflammation and apoptosis 
(20); these stressors are widely acknowledged to regulate the 
pathophysiology of this devastating disorder (Figure 1). Furthermore 
mitochondrial dysregulation and the resultant elevation in mROS have been 
shown in in vivo murine studies to mediate development of hypertension (21), 
the dominant clinical characteristic for pre-eclampsia. There is a substantial 
mitochondrial content in the placenta, in part to mediate the elevated 
metabolic activities during pregnancy. It has been shown that mitochondrial 
dysfunction is a pathogenic mediator of oxidative stress in pre-eclampsia, with 
increased mitochondrial lipid peroxidation and enhanced susceptibility to 
oxidation evident in mitochondria of pre-eclamptic placentas (22).  
 Further evidence of a pathogenic link between distortion of mitochondrial 
function and development of pre-eclampsia was recently described where the 
activity of the placental mitochondrial electron transport chain was greatly 
exaggerated in pre-term pre-eclampsia patients compared to normotensive 
controls and this activity correlated with elevated soluble levels of anti-
angiogenic factors (23). Furthermore a recent murine study established a 
significant link between placental STOX1 expression (pre-eclampsia 
susceptibility gene) and dysregulated mitochondrial dynamics with a 
consequent increase in mROS production (24). 
 
A study by Qiu et al. used mitochondrial DNA (mtDNA) as a biomarker of 
systemic mitochondrial dysfunction and recorded an increase in copy number 
in sera from pre-eclampsia patients (25), this was in accordance with 
evidence of increased placental mtDNA levels in pre-eclampsia (26). Further 
placental mtDNA studies have found a significant correlation between mtDNA 
copy number and markers of distorted mitochondrial biogenesis and cellular 
senescence (27, 28). Quantitative analysis of the mitochondrial placental 
proteome in pre-eclampsia reported increased abundance of proteins involved 
in apoptosis, oxidative stress, ROS generation, in addition to lower 
abundance of proteins regulating fatty acid oxidation (29). These results are 
consistent with other groups who described a reduced capacity for fatty acid 
oxidation in pre-eclampsia placentas (30) and human umbilical vein 
endothelial cells (HUVEC) (31) implying that diminished energy production is 
intrinsically linked to dysregulation of the feto-placental unit. We have recently 
detected increased levels of plasma-induced mitochondrial-specific 
superoxide production in HUVEC’s incubated with plasma from women with 
pre-eclampsia compared with matched controls and non-pregnant controls 
(32). Additionally, we have shown strong evidence of perturbation of 
mitochondrial function in the metabolite profile of plasma samples taken at 
15±1 week’s gestation from patients who developed pre-eclampsia (33). 
 
 
Consequences of the hypothesis 
 
A role for Mitochondrial Therapeutics in Pre-eclampsia? 
Mitochondria are the major source of ROS but correspondingly these 
organelles are also prime targets of cellular ROS. Mitochondrial membrane, 
proteins and mtDNA are acutely susceptible to oxidative damage hence 
mitochondria are prime candidates for therapeutic strategies regardless of 
whether the damage to the actual organelle isn’t the primary pathological 
insult. Despite extensive research, current antioxidant interventions are not 
clinically effective in resisting ROS-mediated pathological pathways. In excess 
of 800 peer-reviewed publications over the past 25 years have supported the 
hypothesis that oxidative damage is involved in the pathophysiology of pre-
eclampsia yet there is a striking disconnect between data implicating oxidative 
processes and the failed vitamins C and E trials for preventing pre-eclampsia 
(34). One very plausible explanation is that these antioxidant nutrient 
regimens have missed the intracellular location, namely the mitochondria; 
hence they have failed to alleviate the pathological oxidative damage.  
 An essential component in the design and use of mitochondrial-targeted 
antioxidant therapies is that they should act on a particular ROS, as previous 
antioxidants have tended to have a broad specificity in the ROS they detoxify 
and their intracellular location. Recent work established that pre-treatment 
with selenomethionine amplified the placental actvity of specific antioxidants 
gluthathione peroxidase and thioredoxin reductase upon exposure to 
oxidative stressors (35).  
 
The membrane potential of mitochondria in vivo is negative inside and much 
greater than in other organelles, which allows lipophilic cations such as 
triphenylphosponium (TPP) to selectively accumulate within mitochondria 
(36). Antioxidants conjugated to TPP therefore can be targeted to 
mitochondria at a dramatically higher concentration, increasing potency and 
allowing less of the compound to be used, thereby reducing 
extramitochondrial metabolism. Recent evidence has identified a prominent 
role for mROS in modulating hypertension (21). Using two in vivo murine 
models of hypertension (AngII-induced and DOCA salt), this group eloquently 
demonstrated that mitochondria-targeted antioxidant therapies (Mito-Tempo) 
alleviated endothelial dysfunction, reduced vascular mitochondrial superoxide 
and subsequent hypertension (21). Interestingly, in both in vivo models of 
hypertension, Mito-Tempo achieved these beneficial effects at a dose 1000-
fold lower than its non-targeted parent compound.  
 
CONCLUSION 
There is substantial evidence indicating a potential pathogenic role for 
dysregulation of mitochondrial function in mediating the clinical characteristics 
of pre-eclampsia. Redox signaling instigated by mROS is now widely 
implicated in a diverse range of biologically important systems. Direct 
evidence of this has transpired in the recent years with insight that 
mitochondria establish and sustain immune cell phenotypes. To date, 
targeting mitochondria have been largely overlooked as a potential 
therapeutic strategy for pre-eclampsia. We suggest that mitochondrial 
pharmacology is feasible, because therapeutics that target a limited number 
of mutual deleterious pathways have the potential to treat patients with pre-
eclampsia. 
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